Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination therapy with antibody-drug conjugates

A technology for coupling compounds and antibodies, applied in the field of combined therapy with antibody-drug conjugates, can solve the unmet medical needs of HL patients and other problems

Active Publication Date: 2011-02-09
SEATTLE GENETICS INC
View PDF102 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, the medical needs of HL patients remain unmet

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapy with antibody-drug conjugates
  • Combination therapy with antibody-drug conjugates
  • Combination therapy with antibody-drug conjugates

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0480] Example 1 : Antibody-drug conjugate cAC10-vcMMAE (cAC10-MC-vc-PAB-MMAE) in combination with chemotherapy regimens for the treatment of HL

[0481]The effect of combined cAC10-vcMMAE therapy with gemcitabine or ABVD or other chemotherapy regimens was studied in the L540cy tumor model (Francisco et al., Blood 2003; 102:1458-146). To determine the maximum tolerated dose (MTD) of ABVD and gemcitabine, body weights of SCID mice treated with increasing amounts of drug were assessed daily. MTD was assessed by ≥20% weight loss or other signs of morbidity throughout the treatment period and subsequent 2-week recovery period. The time to tumor quadrupling or tripling was chosen as the time to endpoint (TTE), and nonlinear regression analysis was performed on individual tumor growth data sets for each experimental animal in exponential growth phase to determine this endpoint. Time to tumor quadrupling was calculated based on tumor volume at the start of treatment. The TTE valu...

Embodiment 2

[0505] Example 2: Antibody-drug conjugate cAC10-mcMMAF combined with gemcitabine for the treatment of HL

[0506] The effect of cAC10-mcMMAF treatment in combination with gemcitabine was studied in the same manner as the experiments used for cAC10-vcMMAE. Choose 1 mg / kg, q4dx3 regimen for cAC10-mcMMAF. On Day 51 of the trial, 9 / 10 sustained responses were observed in the combination arm compared with 0 / 10 in the cAC10-mcMMAF monotherapy arm and 0 / 10 in the gemcitabine single arm arm. 10 sustained responses. The experiment is on day 51 and has not yet been completed.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods for the treatment of Hodgkin's lymphoma comprising administering both a chemotherapeutic regimen and an antibody-drug conjugate compound to a subject in need thereof are provided.

Description

[0001] continue to apply [0002] This application claims U.S. Provisional Patent Application No. 60 / 979,594, filed December 10, 2007; U.S. Provisional Patent Application No. 60 / 027,668, filed November 2, 2008; and U.S. Provisional Patent Application, filed March 28, 2008 Priority of No. 61,040,641; the entire contents of which are incorporated herein by reference. technical field [0003] The present invention relates to methods of treatment of Hodgkin's lymphoma and the like, said methods comprising administering a chemotherapy regimen and an antibody-drug conjugate compound to a subject in need thereof. Background technique [0004] Hodgkin's lymphoma (HL) is a neoplasm of the lymphoid tissue defined histopathologically by the presence of malignant Hodgkin-Rie-Sch (HRS) cells. A characteristic surface antigen expressed on HRS cells is CD30. In the United States and Canada, an estimated 8,000 new cases of HL are diagnosed each year. Advances in the use of combined chemo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/00A61K31/7064
CPCA61K31/7064A61K47/48561A61K47/48415C07K16/2878A61K39/39533A61K47/6811A61K47/6849A61P35/00A61P43/00A61K2300/00A61K39/395
Inventor E·奥夫拉佐格鲁E·西弗斯H·格伯
Owner SEATTLE GENETICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com